Showing 1,681 - 1,700 results of 101,477 for search '(( 5 non decrease ) OR ( 5 ((((step decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.72s Refine Results
  1. 1681

    Subgroup analyses of the association between decreases in serum UA levels and poor functional outcome at 3 months. by Kuniyuki Nakamura (13040299)

    Published 2023
    “…<p>The ORs and 95% CIs of poor functional outcome (defined as an mRS score of 3–6 at 3 months) are shown according to UA decrease rate grade (G1 to G4) in each subgroup. The subgroups included (<b>A</b>) age (<75 or ≥75 years), (<b>B</b>) sex (women or men), (<b>C</b>) stroke subtype (non-cardioembolic or cardioembolic), (<b>D</b>) neurological severity (NIHSS <5 or ≥5), (<b>E</b>) CKD (presence or absence), and (<b>F</b>) UA level on admission (<292 or ≥292 μmol/L for women, <351 or ≥351 μmol/L for men). …”
  2. 1682

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  3. 1683

    Image_5_Global burden of non-communicable chronic diseases associated with a diet low in fruits from 1990 to 2019.JPEG by Shijie Pan (6584711)

    Published 2023
    “…However, both ASMR and ASDR showed a decreasing trend. The fastest decline in ASMR and ASDR was in stroke, with AAPC of −2.13 (95% CI: −2.22, −2.05, p < 0.05) and −0.56 (95% CI: −0.62, −0.51, p < 0.05), respectively. …”
  4. 1684
  5. 1685
  6. 1686
  7. 1687
  8. 1688

    HFD Developmentally Decreases B Lymphopoiesis: RT-PCR was performed on whole BM extracted from the femur. by Benjamin J. Adler (417336)

    Published 2014
    “…(c) Pax-5 expression, which represents an intermediate step in B lymphopoiesis did not appear reduced at 2D, but was significantly decreased subsequently. …”
  9. 1689
  10. 1690
  11. 1691
  12. 1692
  13. 1693

    Rat tickling: A systematic review of applications, outcomes, and moderators by Megan R. LaFollette (3911140)

    Published 2017
    “…The most common method used for tickling was cycling through 15 seconds of tickling and 15 seconds of rest for 2 minutes for 3 to 5 days. Experiments with a control for tickling (N = 22) showed that tickling increases positive vocalization, approach behavior, decreases anxiety measures, improves handling, and in some cases decreases stress hormones. …”
  14. 1694
  15. 1695
  16. 1696

    Self-Diffusive Properties of the Intrinsically Disordered Protein Histatin 5 and the Impact of Crowding Thereon: A Combined Neutron Spectroscopy and Molecular Dynamics Simulation S... by Eric Fagerberg (6662456)

    Published 2022
    “…Intrinsically disordered proteins (IDPs) are proteins that, in comparison with globular/structured proteins, lack a distinct tertiary structure. Here, we use the model IDP, Histatin 5, for studying its dynamical properties under self-crowding conditions with quasi-elastic neutron scattering in combination with full atomistic molecular dynamics (MD) simulations. …”
  17. 1697

    Gramine Derivatives Targeting Ca<sup>2+</sup> Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases by Rocío Lajarín-Cuesta (1530580)

    Published 2016
    “…Hence, we propose this multitarget approach as a new and promising strategy for the treatment of neurodegenerative diseases.…”
  18. 1698
  19. 1699
  20. 1700

    datasheet1_Allopregnanolone Decreases Evoked Dopamine Release Differently in Rats by Sex and Estrous Stage.docx by Ana Paula S. Dornellas (9983996)

    Published 2021
    “…As allopregnanolone is a potent positive allosteric modulator of GABA<sub>A</sub> receptors, and GABA<sub>A</sub> receptors can regulate dopamine release, we hypothesized that allopregnanolone would reduce phasic fluctuations in mesolimbic dopamine release that are important in learning and reward processing. …”